Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet primary endpoints. Read the update.
Importance Rank:
1
Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet primary endpoints. Read the update.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.